Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$31.50 USD
-1.19 (-3.64%)
Updated May 24, 2024 04:00 PM ET
After-Market: $31.50 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 121 - 140 ( 299 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended September 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
FDA Accepts Mitapivat NDA, Grants Priority Review; Maintain Buy Rating and $93 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended July 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
2Q2021 Financial Updates Show Agios is in Full Reset Mode; Reiterate Buy and Raise PT to $93
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended July 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Files MAA With EMA a Bit Ahead of Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Submits NDA for Mitapivat a Bit Earlier Than Expected, But Anticipate Minimal Impact on Stock Price
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 18
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Additional Thoughts on Mitapivat Post EHA Conference Call; Reiterate Buy at $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Reports Positive Phase 2 and 3 mitapivat Data at EHA2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 11
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Initiating Coverage With a Buy Rating and $88 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M